Drug intelligence / Profile preview

AD301

Development stage: Preclinical
Lead developer: Shenzhen Zero-One Life Technology
Modality: Small Molecules
Administration: Oral

Overview

AD301 is an orally administered small molecule new molecular entity (NME) being developed by Shenzhen 01 Life Technology Co., Ltd (01Life) for the treatment of atopic dermatitis. The compound is derived from metabolites of human skin commensal bacteria, representing a microbiome-based approach to dermatological therapy. AD301 is currently in the IND-enabling stage of development, aiming to provide a systemic treatment option for patients with atopic dermatitis.

Beyond the preview

Go deeper on AD301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD301.

Explore the full profile